
Biocon Biologics inks licence agreement with Regeneron to commercialise Yesafili
Biocon Biologics Ltd (BBL), the biosimilars company and subsidiary of Biocon Ltd, has announced a licence agreement with Regeneron to commercialise Yesafili, a drug used to treat ophthalmological conditions. The agreement allows the company to launch the …